Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1(GLP-1) Receptor Agonists
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sudipta Sen, MD,FASA
- Phone Number: 713-500-6200
- Email: Sudipta.Sen@uth.tmc.edu
Study Contact Backup
- Name: Omonele Nwokolo
- Phone Number: 713-500-6200
- Email: Omonele.O.Nwokolo@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients taking GLP-1receptor agonists (N=62)
- Patients not taking GLP-1 receptor agonists (N=62)
Exclusion Criteria:
- Previous gastric resection or bypass
- Gastric band in situ
- Previous fundoplication
- Large hiatal hernia
- Pregnant patients
- Recent trauma
- Inability to turn to the right lateral decubitus position
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group G: Patients taking GLP-1receptor agonists
|
Patient will be scanned first in the supine position and then in the right lateral decubitus position.
The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region.
Qualitative and quantitative assessments will be done.
|
|
Group C: Patients not taking GLP-1 receptor agonists (control group)
|
Patient will be scanned first in the supine position and then in the right lateral decubitus position.
The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region.
Qualitative and quantitative assessments will be done.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects that are at risk for aspiration
Time Frame: end of ultrasound
|
Risk for aspiration is indicated by the presence of solids, thick fluid, or clear fluids >1.5ml/kg in the gastric antrum in the right lateral decubitus position
|
end of ultrasound
|
|
Number of subjects that are at low risk for aspiration
Time Frame: end of ultrasound
|
Low risk for aspiration is indicated by a collapsed gastric antrum or clear fluids <1.5ml/kg in the gastric antrum in the right lateral decubitus position.
|
end of ultrasound
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Age
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Number of participants that are male as indicated in the medical records
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Number of participants that are female as indicated in the medical records
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Body mass Index (BMI)
Time Frame: end of ultrasound
|
Body Mass Index (BMI) is calculated as the body mass in kilograms (kg) divided by the square of the body height in meters, and is expressed in units of kg/m2.
|
end of ultrasound
|
|
Physical status as assessed by the American Society of Anesthesiologists (ASA) physical status classification system
Time Frame: end of ultrasound
|
The classification ranges from American Society of Anesthesiologists (ASA)1 (normal healthy person ) to ASA IV (A patient with severe systemic disease that is a constant threat to life)
|
end of ultrasound
|
|
Number of participants with diabetes
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Number of participants with reported nothing by mouth (NPO) status
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Pain severity as assessed by the numeric scale
Time Frame: end of ultrasound
|
This is a 11 point scale with scores ranging from 0 (no pain) to 10 (worst imaginable pain)
|
end of ultrasound
|
|
Number of participants with Gastroesophageal reflux disease (GERD)
Time Frame: end of ultrasound
|
end of ultrasound
|
|
|
Number of participants that have use opioids preoperatively
Time Frame: end of ultrasound
|
end of ultrasound
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sudipta Sen, MD,FASA, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-23-0300
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.